Phio Pharmaceuticals

Region	Nordamerika
ISIN	US71880W2044
Sektor	Biotechnologie
Website	http://www.phiopharma.com

Phio Pharmaceuticals is focused on developing the next generation of immuno-oncology therapeutics based on its proprietary self-delivering RNAi (INTASYLTM) therapeutic platform. Immunotherapies harness our immune system to restore surveillance of tumors that evade detection – a potential curative medicine. INTASYLTM therapeutics can be used as a standalone treatment or in combination with other modalities.